Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential
MWN-AI** Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is expressing strong support for President Donald J. Trump’s recent executive order aimed at expanding access to in vitro fertilization (IVF). This initiative, announced on February 18, 2025, aims to reduce high out-of-pocket costs associated with IVF, which can range between $12,000 and $25,000 per cycle, thereby making fertility treatments more accessible to families.
The company aligns this initiative with its innovative OvaStem® program, designed to enhance reproductive health through advanced regenerative medicine. OvaStem® has shown promising results, boasting an 85% improvement in hormonal function and a 70% success rate in achieving healthy pregnancies using patients' own eggs. This is especially significant for women with Primary Ovarian Insufficiency (POI), who often face low odds for spontaneous pregnancies and typically rely on donor eggs.
Creative Medical Technology Holdings is integrating its OvaStem® program with its AlloStem® platform, currently involved in two FDA-cleared clinical trials, further enhancing the potential of its offerings. In addition, the company has sought Orphan Drug Designation for POI, showcasing its commitment to pioneering fertility solutions.
Timothy Warbington, the company’s president and CEO, praised the executive order as a milestone for expanding fertility care, stating that Creative Medical Technology is well-positioned to lead in this field with its expertise and a growing pipeline of treatments. The firm emphasizes its goal to provide women with affordable, effective infertility solutions, heralding the potential for broader access to these technologies as federal initiatives unfold.
Creative Medical Technology Holdings stands as a key player in regenerative medicine, dedicated to addressing pressing medical challenges and improving reproductive health outcomes. For more information about their OvaStem® program, visit their website.
MWN-AI** Analysis
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has positioned itself as a notable player in the biotechnology sector, particularly with the recent endorsement of President Trump's executive order to expand access to in vitro fertilization (IVF) services. The executive order aims to make fertility treatments more affordable, which may significantly enhance the adoption of advanced reproductive technologies like the company's OvaStem® program.
OvaStem® boasts impressive clinical outcomes, including an 85% improvement in hormonal function and a 70% success rate in achieving viable pregnancies using a patient's own eggs. By offering a personalized alternative to traditional IVF, particularly for patients suffering from Primary Ovarian Insufficiency (POI), Creative Medical Technology Holdings is poised to capture a larger market share as financial barriers to treatment decrease.
Given the pivotal nature of the primary ovarian insufficiency market—which traditionally offers low conception rates and often requires donor eggs—the company’s rapid autologous therapy platform could revolutionize approaches to fertility treatment. The integration of the AlloStem® platform further diversifies the company’s offerings, ensuring a robust pipeline for future growth.
Investors might view the favorable regulatory landscape and increased accessibility to fertility treatments as a compelling growth narrative for CELZ. As regulations promote lower out-of-pocket costs for patients, demand for innovative solutions like OvaStem® is expected to rise. This could enhance the company's financial performance and drive shareholder value over time.
Overall, based on the strong fundamentals highlighted by recent advancements and supportive government initiatives, Creative Medical Technology Holdings represents an intriguing investment opportunity within the biotechnology sector. Investors should monitor developments related to the implementation of the executive order and continue to assess the company's clinical progress in the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a leading biotechnology innovator in regenerative medicine, enthusiastically supports President Donald J. Trump’s executive order expanding access to in vitro fertilization (IVF). This initiative directly aligns with the company’s vision to transform reproductive health through its groundbreaking OvaStem ® program, which has demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient’s own eggs—all with no safety concerns at up to five years post-treatment.
Patients with Primary Ovarian Insufficiency (POI) typically face only a 5-10% chance of spontaneous pregnancy and must rely on donor eggs for conception. OvaStem ® changes this paradigm by leveraging the company’s rapid autologous therapy platform to harness the regenerative properties of a patient’s own cells, providing a novel, personalized alternative to traditional IVF. Further enhancing this breakthrough, the next-generation OvaStem® integrates the company’s AlloStem ® platform, which is already being utilized in two FDA-cleared U.S. clinical trials. Additionally, Creative Medical Technology Holdings has filed for Orphan Drug Designation for POI, reinforcing its leadership in fertility innovation.
The executive order, signed on February 18, 2025, mandates the Domestic Policy Council to deliver recommendations within 90 days to lower out-of-pocket IVF costs, which currently range from $12,000 to $25,000 per cycle, making treatment inaccessible for many families. By removing these financial barriers, the administration’s plan paves the way for greater adoption of advanced fertility technologies.
"The President’s executive order is a historic step toward expanding fertility care, and we are thrilled to contribute to this movement with our patented cutting-edge OvaStem ® program," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "With our unmatched expertise in regenerative medicine and a growing pipeline of innovative treatments, we are uniquely positioned to redefine reproductive health and provide new hope to millions of families."
"Our goal is to provide women with the safest, most effective, and affordable infertility solutions possible," added Courtney Bartlett, DNP, Director of Clinical Operations. "The President’s commitment to reducing financial hurdles will allow more families to access fertility treatments, and OvaStem ® stands at the forefront of this revolution."
Creative Medical Technology Holdings continues to lead the charge in regenerative medicine, with a robust portfolio of proprietary technologies and clinical programs aimed at addressing some of the most pressing medical challenges. As federal efforts to expand fertility care progress, the company remains fully committed to advancing innovative solutions that empower families and drive shareholder value.
For more information about the OvaStem ® program and other regenerative therapies, please visit www.creativemedicaltechnology.com . * whitehouse.gov
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology, and orthopedics and is traded on NASDAQ under the ticker symbol CELZ. For further information about the Company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
FAQ**
How does Creative Medical Technology Holdings Inc. CELZ plan to leverage the recent executive order to expand its OvaStem® program's market reach and accessibility for families seeking fertility treatments?
What measures is Creative Medical Technology Holdings Inc. CELZ implementing to ensure the safety and efficacy of the OvaStem® program, especially considering its pioneering approach in regenerative medicine?
In what ways does Creative Medical Technology Holdings Inc. CELZ intend to utilize the Orphan Drug Designation for Primary Ovarian Insufficiency (POI) to boost its research and commercial prospects?
How will the reduction of out-of-pocket IVF costs, as mandated by the executive order, affect the adoption and growth trajectory of Creative Medical Technology Holdings Inc. CELZ’s innovative therapeutic solutions?
**MWN-AI FAQ is based on asking OpenAI questions about Creative Medical Technology Holdings Inc. (NASDAQ: CELZ).
NASDAQ: CELZ
CELZ Trading
3.38% G/L:
$1.99 Last:
5,542 Volume:
$1.945 Open:
